Granules India Limited (GRANULES.BO)
INR 444.65
(1.8%)
INR 444.65
(1.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.28 Billion INR | 9.94% |
| 2022 | 8.44 Billion INR | -8.35% |
| 2021 | 9.21 Billion INR | 14.15% |
| 2020 | 8.07 Billion INR | 14.33% |
| 2019 | 7.06 Billion INR | -22.24% |
| 2018 | 9.08 Billion INR | 3.01% |
| 2017 | 8.81 Billion INR | 43.55% |
| 2016 | 6.14 Billion INR | 37.46% |
| 2015 | 4.46 Billion INR | -13.95% |
| 2014 | 5.19 Billion INR | 21.96% |
| 2013 | 4.25 Billion INR | 79.04% |
| 2012 | 2.37 Billion INR | 31.31% |
| 2011 | 1.81 Billion INR | 44.56% |
| 2010 | 1.25 Billion INR | -5.98% |
| 2009 | 1.33 Billion INR | -21.87% |
| 2008 | 1.7 Billion INR | 27.39% |
| 2007 | 1.33 Billion INR | 37.69% |
| 2006 | 972.18 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 3.81 Billion INR | -58.96% |
| 2023 Q1 | 2.91 Billion INR | -65.48% |
| 2023 FY | 9.28 Billion INR | 9.94% |
| 2023 Q4 | 9.28 Billion INR | 197.74% |
| 2023 Q3 | 3.11 Billion INR | -71.24% |
| 2023 Q2 | 10.84 Billion INR | 271.92% |
| 2022 FY | 8.44 Billion INR | -8.35% |
| 2022 Q3 | 5.59 Billion INR | -17.97% |
| 2022 Q4 | 8.44 Billion INR | 50.89% |
| 2022 Q1 | 3.96 Billion INR | -57.01% |
| 2022 Q2 | 6.82 Billion INR | 72.27% |
| 2021 Q2 | 8.91 Billion INR | 238.48% |
| 2021 Q4 | 9.21 Billion INR | 157.0% |
| 2021 FY | 9.21 Billion INR | 14.15% |
| 2021 Q3 | 3.58 Billion INR | -59.76% |
| 2021 Q1 | 2.63 Billion INR | -67.39% |
| 2020 Q4 | 8.07 Billion INR | 217.64% |
| 2020 FY | 8.07 Billion INR | 14.33% |
| 2020 Q2 | 5.53 Billion INR | 95.08% |
| 2020 Q3 | 2.54 Billion INR | -54.11% |
| 2020 Q1 | 2.83 Billion INR | -59.79% |
| 2019 Q3 | 1.07 Billion INR | -85.49% |
| 2019 Q4 | 7.06 Billion INR | 559.07% |
| 2019 Q1 | 895.57 Million INR | -90.14% |
| 2019 Q2 | 7.38 Billion INR | 724.78% |
| 2019 FY | 7.06 Billion INR | -22.24% |
| 2018 Q4 | 9.08 Billion INR | 653.23% |
| 2018 Q3 | 1.2 Billion INR | -87.77% |
| 2018 Q2 | 9.85 Billion INR | 742.17% |
| 2018 Q1 | 1.17 Billion INR | -86.72% |
| 2018 FY | 9.08 Billion INR | 3.01% |
| 2017 Q1 | 522.73 Million INR | -91.49% |
| 2017 Q3 | 1.47 Billion INR | -76.37% |
| 2017 Q2 | 6.23 Billion INR | 1092.26% |
| 2017 Q4 | 8.81 Billion INR | 498.49% |
| 2017 FY | 8.81 Billion INR | 43.55% |
| 2016 Q3 | 351.2 Million INR | -93.28% |
| 2016 Q4 | 6.14 Billion INR | 1648.66% |
| 2016 FY | 6.14 Billion INR | 37.46% |
| 2016 Q1 | 1.41 Billion INR | -68.24% |
| 2016 Q2 | 5.22 Billion INR | 268.11% |
| 2015 Q2 | 2.97 Billion INR | 355.58% |
| 2015 Q4 | 4.46 Billion INR | 366.49% |
| 2015 FY | 4.46 Billion INR | -13.95% |
| 2015 Q1 | 653.06 Million INR | -87.42% |
| 2015 Q3 | 957.73 Million INR | -67.81% |
| 2014 Q2 | 4.03 Billion INR | 865.35% |
| 2014 FY | 5.19 Billion INR | 21.96% |
| 2014 Q4 | 5.19 Billion INR | 1014.29% |
| 2014 Q3 | 465.94 Million INR | -88.44% |
| 2014 Q1 | 417.47 Million INR | -90.19% |
| 2013 Q2 | 2.63 Billion INR | 414.67% |
| 2013 FY | 4.25 Billion INR | 79.04% |
| 2013 Q3 | 684.7 Million INR | -74.0% |
| 2013 Q1 | 511.64 Million INR | -78.48% |
| 2013 Q4 | 4.25 Billion INR | 521.75% |
| 2012 Q2 | 1.33 Billion INR | 0.0% |
| 2012 Q4 | 2.37 Billion INR | 0.0% |
| 2012 FY | 2.37 Billion INR | 31.31% |
| 2011 FY | 1.81 Billion INR | 44.56% |
| 2010 FY | 1.25 Billion INR | -5.98% |
| 2009 FY | 1.33 Billion INR | -21.87% |
| 2008 FY | 1.7 Billion INR | 27.39% |
| 2007 FY | 1.33 Billion INR | 37.69% |
| 2006 FY | 972.18 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -140.223% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -151.45% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 426.694% |
| Indoco Remedies Limited | 6.47 Billion INR | -43.397% |
| Achyut Healthcare Limited | -3.74 Million INR | 248012.173% |
| Ajanta Pharma Limited | -954.9 Million INR | 1072.541% |
| Alkem Laboratories Limited | -1.6 Billion INR | 677.034% |
| Alpa Laboratories Limited | 35.36 Million INR | -26161.318% |
| Brooks Laboratories Limited | 49.48 Million INR | -18666.879% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 285.275% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -181.507% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 902.14% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 28.082% |
| Eris Lifesciences Limited | 13.8 Billion INR | 32.736% |
| FDC Limited | -57.75 Million INR | 16180.465% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 316.715% |
| Gufic Biosciences Limited | 3.19 Billion INR | -190.729% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 323.613% |
| Ipca Laboratories Limited | 11.41 Billion INR | 18.645% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 768.148% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -380.454% |
| Lasa Supergenerics Limited | 205.79 Million INR | -4412.554% |
| Laurus Labs Limited | 24.38 Billion INR | 61.915% |
| Lupin Limited | 17.19 Billion INR | 45.983% |
| Mankind Pharma Limited | -9.9 Billion INR | 193.73% |
| Medicamen Biotech Limited | 160.31 Million INR | -5692.803% |
| Medico Remedies Limited | 78.67 Million INR | -11703.691% |
| Megasoft Limited | 1.28 Billion INR | -622.397% |
| NATCO Pharma Limited | -5.81 Billion INR | 259.649% |
| Piramal Pharma Limited | 42.27 Billion INR | 78.033% |
| RPG Life Sciences Limited | -364.7 Million INR | 2646.419% |
| Sigachi Industries Limited | 859.94 Million INR | -979.923% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 112.815% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -6305.743% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -19996.492% |
| Unichem Laboratories Limited | 931.91 Million INR | -896.527% |
| Wanbury Limited | 1.1 Billion INR | -739.769% |
| Windlas Biotech Limited | -273.04 Million INR | 3501.256% |
| ZIM Laboratories Limited | 983.6 Million INR | -844.159% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -137.392% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 1086.068% |
| Divi's Laboratories Limited | -39.77 Billion INR | 123.351% |
| Hester Biosciences Limited | 2.29 Billion INR | -305.406% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 495.519% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 3832.753% |
| Bal Pharma Limited | 1.26 Billion INR | -634.97% |
| Strides Pharma Science Limited | 23.25 Billion INR | 60.069% |
| Venus Remedies Limited | -267.7 Million INR | 3569.103% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -255.557% |
| Nectar Lifesciences Limited | 6.15 Billion INR | -50.826% |
| Shilpa Medicare Limited | 9.06 Billion INR | -2.395% |
| Aarti Drugs Limited | 5.54 Billion INR | -67.378% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 943.257% |
| Suven Life Sciences Limited | -1.63 Billion INR | 668.8% |
| Ind-Swift Limited | 9.5 Billion INR | 2.333% |
| Valiant Laboratories Limited | -295.03 Million INR | 3247.723% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -229.179% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 7.401% |
| Themis Medicare Limited | 764.96 Million INR | -1114.02% |
| Hikal Limited | 7.96 Billion INR | -16.566% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 70.824% |
| Sequent Scientific Limited | 4.17 Billion INR | -122.245% |
| Novartis India Limited | -5.89 Billion INR | 257.641% |
| Wockhardt Limited | 18.27 Billion INR | 49.169% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 65.696% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 50445.82% |
| Neuland Laboratories Limited | -214.05 Million INR | 4438.446% |
| Morepen Laboratories Limited | -231.17 Million INR | 4117.229% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -7636.477% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -851.7% |